Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DNL 747

Drug Profile

DNL 747

Alternative Names: DNL747; SAR 443060

Latest Information Update: 24 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harvard University
  • Developer Denali Therapeutics Inc
  • Class Antidementias; Small molecules
  • Mechanism of Action RIPK1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease; Amyotrophic lateral sclerosis

Most Recent Events

  • 05 Dec 2019 Denali Therapeutics completes a phase I trial for Alzheimer Disease in the Netherlands (NCT03757325)
  • 07 Nov 2019 Phase-I clinical trials in Amyotrophic lateral sclerosis (Treatment-experienced) in USA, prior November 2019 (PO) (NCT03757351)
  • 07 Nov 2019 Denali Therapeutics initiates enrolment in a extension trial for Amyotrophic lateral sclerosis in Netherlands, prior November 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top